ArticleFrontiers in immunology2025
Impact of pregnant mothers' previous COVID-19 infection and vaccination on newborns' serological profiling.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pregnant women and newborns are at-risk groups for coronavirus disease 2019 (COVID-19). There is a paucity of evidence to prove the degree of perinatal passive immunity transfer from COVID-19-vaccinated or COVID-19-infected mothers to their newborns. Methods: We prospectively investigated the vaccination and infection status of 70 women included in the study, as well as the serological characteristics of 72 newborns, to investigate the Results: A total of 70 pregnant mothers were included in the study after providing signed informed consent. After delivery, cord blood samples were collected from all 72 newborns included in the study. The COVID-19-vaccinated group had significantly higher (p < 0.001) values of both antibodies (NTAb*3.31 and S-RBD*1.15) in the cord blood across both the COVID-19-positive and COVID-19-negative groups. The antibody titres were the lowest in mothers who were not vaccinated and the highest in those who received three vaccination doses (p < 0.001). Multivariate linear regression analysis was performed using dependent variables NTAb*3.31 and S-RBD*1.15 antibodies and independent predictor variables nationality, infant's gender, COVID-19 vaccination status, and COVID-19 test status; the multivariate linear regression analysis results indicated that vaccination against COVID-19 remained a potential significant (p < 0.0001) predictor for both NTAb*3.31 and S-RBD*1.15 antibodies after adjusting other potential predictor variables. Conclusions: In our study, we found significantly higher titres of NTAb*3.31 and S-RBD*1.15 antibodies in newborns' cord blood whose mothers had previous COVID-19 infection or received COVID-19 vaccination; however, these titres were higher in the case of vaccination than previous infection. The more doses of vaccine received, the higher the antibody levels in newborns' cord blood. This indicates transplacental immunity transmission from mothers to their newborns after previous COVID-19 vaccination or infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.